Carolyn Myers
Follow
Get notifications in MyBN when activity occurs.
Carolyn Myers
Non-Executive Director / Mayne Pharma Group
Dr Carolyn Myers is a pharmaceutical executive with over 30 years of experience in the pharmaceutical industry.
Dr Myers is the chief executive of FendX technologies, a medical technology company formed to develop and commercialise products using a unique pathogen-repelling technology. She is also principal of BioEnsemble which provides consulting services to small and mid-size pharma, biotech and medical technology companies.
Dr Myer had previously held senior leadership roles at Allergan, Forest Labs, Mylan (now Viatris) and Pharmacia (now Pfizer). She was also vice president of global alliance management and international business development at Allergan, vice president of marketing at Forest Laboratories, president of Dey Laboratories, and president of Mylan Technologies.
Dr Myers is the chief executive of FendX technologies, a medical technology company formed to develop and commercialise products using a unique pathogen-repelling technology. She is also principal of BioEnsemble which provides consulting services to small and mid-size pharma, biotech and medical technology companies.
Dr Myer had previously held senior leadership roles at Allergan, Forest Labs, Mylan (now Viatris) and Pharmacia (now Pfizer). She was also vice president of global alliance management and international business development at Allergan, vice president of marketing at Forest Laboratories, president of Dey Laboratories, and president of Mylan Technologies.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 82nd | Mayne Pharma Group | 105% | -13% |
| 357th | PWR Holdings | 24% | 29% |
| 594th | Regal Investment Fund | 5% | |
| 1001st | Retail Food Group | -19% | -23% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 348th |  | Mayne Pharma Group | $193.0m |
| 413th |  | PTB Group | $125.2m |
| 414th | | Regal Investment Fund | $124.8m |
| 417th | | Retail Food Group | $120.7m |
| 418th | | PWR Holdings | $120.2m |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Non-Executive Director, Mayne Pharma Group | 08 Feb 2022 |
